Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) – Pipeline Review, H2 2016’, provides in depth analysis on Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted pipeline therapeutics.

The report provides comprehensive information on the Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14)

The report reviews Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted therapeutics and enlists all their major and minor projects

The report assesses Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Gilead Sciences Inc

MedDay SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC

6.4.1.2 or EC

6.3.4.14) Overview 6

Therapeutics Development 7

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC

6.4.1.2 or EC

6.3.4.14) - Products under Development by Stage of Development 7

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC

6.4.1.2 or EC

6.3.4.14) - Products under Development by Therapy Area 8

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC

6.4.1.2 or EC

6.3.4.14) - Products under Development by Indication 9

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC

6.4.1.2 or EC

6.3.4.14) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC

6.4.1.2 or EC

6.3.4.14) - Products under Development by Companies 12

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC

6.4.1.2 or EC

6.3.4.14) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 17

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC

6.4.1.2 or EC

6.3.4.14) - Companies Involved in Therapeutics Development 19

Gilead Sciences Inc 19

MedDay SA 20

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC

6.4.1.2 or EC

6.3.4.14) - Drug Profiles 21

Antisense Oligonucleotide to Inhibit ACC2 for Obesity - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

biotin - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

ND-630 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

ND-646 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

ND-654 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC

6.4.1.2 or EC

6.3.4.14) - Featured News & Press Releases 31

Sep 19, 2016: Salk Institute: Targeting fat to treat cancer 31

Sep 14, 2016: Positive Preclinical Data With MD1003 (High Dose Pharmaceutical Grade Biotin) in X-Linked Adrenoleukodystrophy to be Presented at European Committee for Treatment and Research in Multiple Sclerosis 2016 32

Sep 02, 2016: MedDay Announces Publication of MD1003 Phase IIb/III Study in the Multiple Sclerosis Journal 32

May 25, 2016: MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial 33

Apr 21, 2016: MedDay reports full data from pivotal Phase IIb/III MS-SPI / MS-ON studies with MD1003 in Multiple Sclerosis at AAN 34

Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003 36

Oct 07, 2015: MedDay reports additional positive analyses of its pivotal study with MD1003 in patients with primary and secondary Progressive Multiple Sclerosis 38

Aug 06, 2015: Medical Need Europe appoints Durbin as latest distribution partner 39

Jun 19, 2015: MedDay reports additional positive data of its pivotal Phase III study with MD1003 in patients with Progressive Multiple Sclerosis 39

Jun 17, 2015: MedDay and DSM announce a partnership to produce pharmaceutical grade D-Biotin to treat progressive multiple sclerosis 41

Apr 24, 2015: MedDay reports positive pivotal Phase III study results with MD1003 in patients with Progressive Multiple Sclerosis 41

Apr 21, 2015: Nimbus Therapeutics Announces Initiation of Clinical Studies for ACC Inhibitor 42

Apr 17, 2015: MedDay announces its pivotal Phase III study of MD1003 in patients with Progressive Multiple Sclerosis meets primary endpoint 43

Apr 07, 2015: MedDay provides update on pioneering pivotal Phase III study design in Progressive Multiple Sclerosis 44

Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 45

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 18

Pipeline by Gilead Sciences Inc, H2 2016 19

Pipeline by MedDay SA, H2 2016 20

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Molecule Types, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 17

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports